Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sangamo Therapeutics
(NQ:
SGMO
)
1.940
-0.210 (-9.77%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sangamo Therapeutics
< Previous
1
2
3
4
5
6
7
Next >
J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
November 26, 2024
Via
Benzinga
Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
November 19, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results
November 12, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Earnings Scheduled For November 12, 2024
November 12, 2024
Via
Benzinga
Sangamo Therapeutics's Earnings Outlook
November 11, 2024
Via
Benzinga
4 Analysts Have This To Say About Sangamo Therapeutics
October 23, 2024
Via
Benzinga
Why Is Sangamo Therapeutics (SGMO) Stock Up 52% Today?
August 06, 2024
Sangamo Therapeutics stock is heading higher on Tuesday as SGMO investors react to a new $50 million license agreement.
Via
InvestorPlace
Zeta Global, Spirit Airlines And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
November 12, 2024
Via
Benzinga
Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast
November 04, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Booz Allen Posts Upbeat Q3 Earnings, Joins Deckers Outdoor, Saia, Boyd Gaming And Other Big Stocks Moving Higher On Friday
October 25, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
October 23, 2024
Via
Benzinga
Peering Into Sangamo Therapeutics's Recent Short Interest
July 25, 2024
Via
Benzinga
Nasdaq Turns Higher; Verizon Shares Fall After Q3 Results
October 22, 2024
Via
Benzinga
What's Going On With Sangamo Therapeutics Shares Tuesday?
October 22, 2024
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shares are moving higher Tuesday after the company announced the FDA approved an accelerated pathway for ST-920, a potential gene therapy for the treatment of...
Via
Benzinga
Exposures
Product Safety
Crude Oil Rises Sharply; 3M Posts Upbeat Earnings
October 22, 2024
Via
Benzinga
Exposures
Fossil Fuels
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 22, 2024
Via
Benzinga
Dow Falls Over 150 Points; General Motors Tops Q3 Views
October 22, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025
October 22, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
FDA Approves Pfizer's Second Hemophilia Drug With Six Months
October 14, 2024
Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly treatment reduces bleeding rates and offers convenience via an...
Via
Benzinga
Exposures
Product Safety
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results
August 06, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Why Sangamo Therapeutics Stock Is Soaring
August 06, 2024
Sangamo Therapeutics shares are trading higher Tuesday after the company announced it has entered into a license agreement with Genentech to develop intravenously administered genomic medicines for...
Via
Benzinga
Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases
August 06, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics Announces Second Quarter 2024 Conference Call and Webcast
July 30, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Why Is Sangamo Therapeutics (SGMO) Stock Up 40% Today?
July 24, 2024
Little-known firm Sangamo Therapeutics is surging today, with SGMO stock up more than 40% on promising late-stage trial results.
Via
InvestorPlace
Crude Oil Gains 1%; AT&T Shares Rise After Q2 Earnings
July 24, 2024
Via
Benzinga
Exposures
Fossil Fuels
Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
July 26, 2024
Via
Benzinga
Dow Tumbles 300 Points; Tesla Shares Plunge After Q2 Results
July 24, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
July 24, 2024
Via
Benzinga
Sangamo Stock Spikes As Pfizer Partnership Meets Goal In Late-Stage Study
July 24, 2024
Pfizer's Phase 3 AFFINE study of giroctocogene fitelparvovec gene therapy for hemophilia A meets key endpoints, showing a significant reduction in annualized bleeding rate.
Via
Benzinga
Sangamo Therapeutics Reports on Pfizer’s Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate
July 24, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.